Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two- and three-drug combinations of delavirdine, lamivudine and zidovudine

Antiviral Chemistry and Chemotherapy

Volumn 8, Issue 4, 1997, Pages 333-341

  Pagano, P J ^a   Chong, K T ^a  

^a PFIZER INC   (United States)

Author keywords

Delavirdine; Lamivudine; Synergy; Zidovudine

Indexed keywords

ANTIGEN P24; DELAVIRDINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; BLOOD; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 0030825553     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029700800406     Document Type: Article

References (39)

1. Arts EJ & Wainberg MA (1996) Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrobial Agents and Chemotherapy 40: 527-540.
2. Balzarini J, Karlsson A, Perez-Perez M-J, Camarsa M-J & DeClercq E (1993) Knocking-out concentrations of HIV-1 specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug resistant virus. Virology 196: 576-585.
3. Balzarini J, Pelemans H, Perez-Perez M-J, Sanfelix A, Camarasa MJ, DeClercq E & Karlsson A (1996) Marked inhibitory activity of nonnucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2′,3′-thiacytidine. Molecular Pharmacology 49: 882-890.
4. Belen'kii MS & Schinazi RF (1994) Multiple drug effect analysis with confidence interval. Antiviral Research 25: 1-11.
5. Chong KT (1996) Recent advances in HIV-1 protease inhibitors. Expert Opinion on Investigational Drugs 5: 115-124.
6. Chong KT, Pagano PJ & Hinshaw RR (1994) Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3′-azido-3′-deoxythymidine or 2′,3′-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro. Antimicrobial Agents and Chemotherapy 38: 288-293.
7. Chong KT & Pagano PJ (1997) Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine. Antiviral Research 34: 51-63.
8. Chou T-C & Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation. 22: 27-55.
9. D'Aquila R, Hughes M, Johnson VA, Fischl MA, Sommadossi JP, Liou S-H, Timpone J, Myers M, Basgoz N, Niu M, Hirsch MS and the NIAID AIDS Clinical Trials Group Protocol 241 Investigators (1996) Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection - a randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 124: 1019-1030.
10. Davey RT, Chaitt DG, Reed GF, Freimuth WW, Herpin BR, Metcalf JA, Eastman PS, Falloon J, Kovacs JA, Polis MA, Walker RE, Masur H, Boyle J, Coleman S, Cox SR, Wathen L, Daenzer CL & Lane HC (1996) Randomized, controlled phase I/II trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients. Antimicrobial Agents and Chemotherapy 40: 1657-1664.
11. De Clercq E (1994a) Non-nucleoside reverse transcriptase inhibitors (NNRTIs). Expert Opinion on Investigational Drugs 3: 253-271.
12. De Clercq E (1994b) HIV resistance to reverse transcriptase inhibitors. Biochemical Pharmacology 47: 155-169.
13. Frei III E (1991) Clinical studies of combination chemotherapy for cancer. In Synergism and Antagonism in Chemotherapy. Edited by T-C Chou & DC Rideout. San Diego: Academic Press, pp. 103-109.
14. Freimuth WW (1996) Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. In Antiviral Chemotherapy 4: New Directions for Clinical Application and Research. Edited by J Mills, PA Volberding & L Corey. New York & London: Plenum Press, pp. 279-289.
15. Goldman ME, Nunberg JH, O'Brien JA, Quintero J, Schleif WA, Freund KF, Gaul SL, Saari WS, Wai JS, Hoffman JM, Anderson PS, Hupe DJ, Emini EA & Stern AM (1991) Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proceedings of the National Academy of Sciences, USA 88: 6863-6867.
16. Goodenow M, Huet T, Saurin W, Kwok S, Sninsky J & Wain-Hobson S (1989) HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions. Journal of Acquired Immune Deficiency Syndromes 2: 344-352.
17. Goulden MG, Cammack N, Hopewell PL, Penn CR & Cameron JM (1996) Selection in vitro of an HIV-1 variant resistant to both lamivudine (3TC) and zidovudine. AIDS 10: 101-115.
18. Johnston MI & Hoth DF (1993) Present status and future prospects for HIV therapies. Science 260: 1286-1293.
19. Kavlick MF, Shirasaka T, Kojima E, Pluda JM, Hui Jr F, Yarchoan R & Mitsuya H (1995) Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (-)-2′,3′-dideoxy-3′-thiacytidine. Antiviral Research 28: 133-146.
20. Koyanagi Y, Miles S, Mitsuyasu RT, Merrill JE, Vinters HV & Chen ISY (1987) Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 236: 819-822.
21. Kuritzkes DR, Quinn JB, Benoit SL, Shugarts KL, Griffin A, Bakhtiari M, Poticha D, Eron JJ, Fallon MA & Rubin M (1996) Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 10: 975-981.
22. Lange JMA (1995) Triple combinations: present and future. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 10: S77-S82.
23. Larder BA (1992) 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrobial Agents and Chemotherapy 36: 2664-2669.
24. Larder BA, Kemp SD & Harrigan PR (1995) Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269: 696-699.
25. Mellors JW, Larder BA & Schinazi RF (1995) Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. International Antiviral News 3: 8-12.
26. Merigan TC (1991) Treatment of AIDS with combinations of antiretroviral agents. American Journal of Medicine 90: 8S-17S.
27. Mossman T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods 65: 55-63.
28. Nájera I, Holguin A, Quiñones-Mateu ME, Muñoz-Fernández MA, Nájera R, López-Galindez C & Domingo E (1995) pol Gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. Journal of Virology 69: 23-31.
29. Peterson PK, Gekker G, Hu S & Chao CC (1994) Anti-human immunodeficiency virus type 1 activities of U-90152 and U-75875 in human brain cell cultures. Antimicrobial Agents and Chemotherapy 38: 2465-2468.
30. Pritchard MN, Prichard LE & Shipman Jr C (1993) Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrobial Agents and Chemotherapy 37: 540-545.
31. Richman DD, Rosenthal AS, Skoog M, Eckner RJ, Chou T-C, Sabo JP & Merluzzi VJ (1991) BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrobial Agents and Chemotherapy 35: 305-308.
32. Ritter JM, Lewis LD & Mant TGK (1995) Drug interactions. In A Textbook of Clinical Pharmacology, 3rd edn. London: Edward Arnold, pp. 107-118.
33. Ruiz L, Romeu J, Martinez-Picado J, Schmit J-C, Vandamme A-M, Balagué M, Cabrera C, Puig T, Tural C, Segura A, Sirera G, De Clercq E & Clotet B (1996) Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV + 3TC) combination therapy in patients previously treated with ZDV + ddC. AIDS 10: F61-F66.
34. Schinazi RF, Lloyd Jr RM, Nguyen M-H, Cannon DL, McMillan A, Ilksoy N, Chu CK, Liotta DC, Bazmi HZ & Mellors JW (1993) Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrobial Agents and Chemotherapy 37: 875-881.
35. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, deJong D, Collis P, Danner SA, Mulder J, Loveday C, Christopherson C, Kwok S, Sninsky J & Boucher CAB (1995) Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). Journal of Infectious Diseases 171: 1411-1419.
36. Soo W, Nauss-Karol C, Elkins M, Rooney J & Barry DW (1995) Inter-Company Collaboration Combination Trials. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 10: Supplement, 592-596.
37. Staszewski S, Miller V, Rehmet S, Start T, Decree J, Debrabander M, Peeters M, Andries K, Moeremans M, Deraeymaeker M, Pearce G, Vandenboeck R, Veerbiest W & Stoffels P (1996) Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1 infected patients. AIDS 10: F1-7.
38. Tisdale M, Kemp SD, Parry NR & Larder BA (1993) Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proceedings of the National Academy of Sciences, USA 90: 5653-5656.
39. vonBriesen H, Becker WB, Henko K, Helm EB, Gelderblum HR, Brede HD & Rübsamen-Waigmann H (1987) Isolation frequency and growth properties of HIV-variants: multiple simultaneous variants in a patient demonstrated by molecular cloning. Journal of Medical Virology 23: 51-66.